Aptamer and Peptide-Engineered Polydopamine Nanospheres for Target Delivery and Tumor Perfusion in Synergistic Chemo-Phototherapy of Pancreatic Cancer

作者全名："Liu, Liang; Xiao, Xinyu; Guo, Jiao; Wang, Jianwei; Liu, Shanshan; Wang, Meijiao; Peng, Qiling; Jiang, Ning"

作者地址："[Liu, Liang; Xiao, Xinyu; Guo, Jiao; Wang, Jianwei; Liu, Shanshan; Wang, Meijiao] Chongqing Med Univ, Sch Basic Med Sci, Chongqing 400016, Peoples R China; [Peng, Qiling] Chongqing Med Univ, Sch Basic Med Sci, Chongqing 400016, Peoples R China; [Jiang, Ning] Chongqing Med Univ, Testing Ctr, Dept Pathol & Mol Med Diagnost, Chongqing 400016, Peoples R China; [Jiang, Ning] Chongqing Med Univ, Affiliated Hosp 1, Dept Pathol, Chongqing 400016, Peoples R China"

通信作者："Wang, MJ (通讯作者)，Chongqing Med Univ, Sch Basic Med Sci, Chongqing 400016, Peoples R China.; Peng, QL (通讯作者)，Chongqing Med Univ, Sch Basic Med Sci, Chongqing 400016, Peoples R China.; Jiang, N (通讯作者)，Chongqing Med Univ, Testing Ctr, Dept Pathol & Mol Med Diagnost, Chongqing 400016, Peoples R China.; Jiang, N (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Pathol, Chongqing 400016, Peoples R China."

来源：ACS APPLIED MATERIALS & INTERFACES

ESI学科分类：MATERIALS SCIENCE

WOS号：WOS:000957966900001

JCR分区：Q1

影响因子：8.3

年份：2023

卷号：15

期号：13

开始页：16539

结束页：16551

文献类型：Article

关键词：pancreatic cancer; chemo-phototherapy; desmoplastic stroma; tumor perfusion; controllable release

摘要："Pancreatic cancer (PC) is the fourth leading cause of cancer death, and the 5 year survival rate is only 4%. Chemotherapy is the treatment option for the majority of PC patients diagnosed at an advanced stage, whereas the desmoplastic stroma of PC could block the perfusion of chemotherapeutic agents to tumor tissues and contribute generally to chemoresistance. Therefore, the clinical status of PC calls for an urgent exploration in the effective treatment strategy. Chemo-phototherapy is an emerging modality against malignant tumors, but owing to the low targeting ability of theranostic agents or unspecific accumulation in the tumor region, majority of chemophototherapy techniques have disappointing therapeutic efficiencies. Herein, we have explored CD71-specific targeting aptamers and paclitaxel (PTX)-modified polydopamine (PDA) nanospheres with the conjugation of peptidomimetic AV3 (termed Apt-PDA@PTX/AV3 bioconjugates) to specifically target and combat PC in vivo by synergistic chemo-phototherapy. After the delivery of nanotheranostic agents to the tumor microenvironment (TME) or subsequent endocytic uptake by PC cells, a simultaneous release of AV3 and PTX from Apt-PDA@PTX/AV3 bioconjugates via near-infrared (NIR) irradiation can decrease desmoplastic stroma to enhance tumor perfusion and tumor-killing effects. Meanwhile, PDA cores utilize NIR laser to create unendurable hyperthermia within TME to ""cook"" tumors. Taken together, the current study finally suggests that our Apt-PDA@PTX/AV3 bioconjugates could act as a novel therapeutic approach by synergistic chemophototherapy for the inhibition of PC."

基金机构："National Natural Science Foundation of China [82203310, 81972023]; Natural Science Foundation of Chongqing City [CSTC2020jcyj-msxmX0144, CSTC2021jcyj-msxm0172]; Science and Technology Research Program of Chongqing Education Commission of China [KJQN201900425, KJQN202000401]; Creative Research Group of CQ University [CXQT21017]; Program for Youth Innovation in Future Medicine from Chongqing Medical University"

基金资助正文："This work was supported by the National Natural Science Foundation of China (grant nos. 82203310 and 81972023) , the Natural Science Foundation of Chongqing City (grant nos. CSTC2020jcyj-msxmX0144 and CSTC2021jcyj-msxm0172) , the Science and Technology Research Program of Chongqing Education Commission of China (grant nos. KJQN201900425 and KJQN202000401) , Creative Research Group of CQ University (grant no. CXQT21017) , and Program for Youth Innovation in Future Medicine from Chongqing Medical University. The authors acknowledge with thanks the ethics committee of the first Affiliated Hospital of Chongqing Medical University for the ethical approval of this study."